Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Athanassios (Ethan) Argiris

ECOG-ACRIN Cancer Research Group

Intervention

Bevacizumab(biological)

Enrollment

403 enrolled

Eligibility

18 years · All sexes

Timeline

2008 – 2018

Study locations (20)

• Providence Hospital, Mobile, Alabama, United States
• University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
• Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
• Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
• NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States
• John L McClellan Memorial Veterans Hospital, Little Rock, Arkansas, United States
• University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
• Kaiser Permanente-Anaheim, Anaheim, California, United States
• Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States
• Kaiser Permanente-Bellflower, Bellflower, California, United States
• Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
• Mills-Peninsula Medical Center, Burlingame, California, United States
• East Bay Radiation Oncology Center, Castro Valley, California, United States
• Eden Hospital Medical Center, Castro Valley, California, United States
• Valley Medical Oncology Consultants-Castro Valley, Castro Valley, California, United States
• +5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Cancer of unknown primary site

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07524114
  Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
  University Health Network, Toronto
• RECRUITINGNANCT07283939
  Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
  Alliance for Clinical Trials in Oncology
• RECRUITINGPHASE2NCT06995508
  Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
  Roswell Park Cancer Institute
• RECRUITINGPHASE1NCT06868433
  TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
  Emory University
• RECRUITINGPHASE3NCT06589804
  Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
  National Cancer Institute (NCI)
• RECRUITINGNANCT06662058
  Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
  Emory University
• RECRUITINGPHASE2NCT06636734
  Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
  Emory University
• RECRUITINGNANCT06644716
  [18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary Origin
  Erasmus Medical Center

See all trials for Cancer of unknown primary site →